Perspective Therapeutics Presented Preclinical Data From Two Independent Studies At The World Molecular Imaging Congress On The Potential Of Lead-based Targeted Alpha Particle Therapy Using VMT-α-NET For Neuroendocrine Tumors
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics presented preclinical data from two independent studies at the World Molecular Imaging Congress. The studies show the potential of lead-based targeted alpha particle therapy using VMT-α-NET for neuroendocrine tumors. The administration of fractionated doses of [212Pb]VMT-α-NET shows 100% survival in a robust model of metastatic neuroblastoma.
September 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Perspective Therapeutics' promising preclinical data on VMT-α-NET for neuroendocrine tumors could potentially impact CATX, if there is a connection between the two.
The article mentions Perspective Therapeutics' promising preclinical data on VMT-α-NET for neuroendocrine tumors. However, it does not explicitly mention CATX. If there is a connection between CATX and Perspective Therapeutics or VMT-α-NET, this news could potentially impact CATX. Without further information, the impact is neutral.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50